Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

LUKE WEBB

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1932161916
CMS profile
314032
Location
COLORADO SPRINGS, CO

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$57,423.17

124 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Page 2 of 3; records 51–100 of 124 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

LUKE WEBB

NPI 1932161916 · CMS profile ID 314032

Allopathic & Osteopathic Physicians / Internal Medicine

COLORADO SPRINGS, CO

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 124 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1932161916?year=2023&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
LUKE WEBB, NPI 1932161916, CMS profile ID 314032. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 124 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1932161916?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). LUKE WEBB, NPI 1932161916, CMS profile ID 314032. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 124 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1932161916?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
LUKE WEBB, NPI 1932161916, CMS profile ID 314032, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 124 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1932161916?year=2023&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

124 matching records · $57,423.17 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 124 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 124.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Takeda Pharmaceuticals U.S.A., Inc. $3.8806/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055662311 CMS
Takeda Pharmaceuticals U.S.A., Inc. $28.9506/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055662317 CMS
AstraZeneca Pharmaceuticals LP $15.9706/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014848623 CMS
GENZYME CORPORATION $19.2306/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049967653 CMS
Novartis Pharmaceuticals Corporation $18.7506/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993395231 CMS
Regeneron Healthcare Solutions, Inc. $18.1606/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999527206 CMS
Grifols USA, LLC $18.3705/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011865263 CMS
AstraZeneca Pharmaceuticals LP $24.7105/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015802385 CMS
GENZYME CORPORATION $15.3805/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049967657 CMS
AstraZeneca Pharmaceuticals LP $27.4605/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015886109 CMS
Genentech USA, Inc. $20.2605/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040441347 CMS
Amgen Inc. $3,250.0005/08/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020004897 CMS
AstraZeneca Pharmaceuticals LP $3,250.0005/08/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015936559 CMS
Amgen Inc. $19.7405/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020004885 CMS
Amgen Inc. $3,700.0005/01/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020004895 CMS
AstraZeneca Pharmaceuticals LP $3,700.0005/01/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015152025 CMS
Amgen Inc. $93.7004/27/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020004889 CMS
Amgen Inc. $267.0504/27/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020004891 CMS
Amgen Inc. $58.7604/27/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020004893 CMS
Amgen Inc. $74.2904/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020004899 CMS
Amgen Inc. $3.9504/27/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020004901 CMS
AstraZeneca Pharmaceuticals LP $20.4204/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016117043 CMS
AstraZeneca Pharmaceuticals LP $21.9904/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016195465 CMS
Novartis Pharmaceuticals Corporation $23.3704/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993395227 CMS
Takeda Pharmaceuticals U.S.A., Inc. $3.2004/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055662299 CMS
Takeda Pharmaceuticals U.S.A., Inc. $17.4504/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055662305 CMS
Blueprint Medicines Corporation $36.6604/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051274253 CMS
Amgen Inc. $18.2304/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020004905 CMS
AstraZeneca Pharmaceuticals LP $18.2304/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015938527 CMS
Amgen Inc. $116.0104/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020004887 CMS
AstraZeneca Pharmaceuticals LP $156.4104/13/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011435987 CMS
AstraZeneca Pharmaceuticals LP $116.0104/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011553074 CMS
AstraZeneca Pharmaceuticals LP $74.2904/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014680987 CMS
AstraZeneca Pharmaceuticals LP $267.0504/13/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015234331 CMS
AstraZeneca Pharmaceuticals LP $942.7304/13/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015925259 CMS
GENZYME CORPORATION $15.6604/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049967621 CMS
Takeda Pharmaceuticals U.S.A., Inc. $15.5404/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055662289 CMS
Takeda Pharmaceuticals U.S.A., Inc. $2.6304/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055662293 CMS
Amgen Inc. $1,850.0003/22/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020004909 CMS
AstraZeneca Pharmaceuticals LP $1,850.0003/22/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016273855 CMS
Takeda Pharmaceuticals U.S.A., Inc. $26.6403/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055662277 CMS
Takeda Pharmaceuticals U.S.A., Inc. $2.6503/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055662283 CMS
AbbVie Inc. $15.0903/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999551309 CMS
CSL Behring $34.3903/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1042957279 CMS
Amgen Inc. $103.6703/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020004907 CMS
AstraZeneca Pharmaceuticals LP $103.6703/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015368758 CMS
Takeda Pharmaceuticals U.S.A., Inc. $20.1903/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055662271 CMS
Amgen Inc. $3,700.0003/09/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020004883 CMS
AstraZeneca Pharmaceuticals LP $3,700.0003/09/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015605189 CMS
AstraZeneca Pharmaceuticals LP $3,700.0003/03/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015776994 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $46,637.68 101
PY2020 $6,301.54 56
PY2021 $23,392.42 103
PY2022 $69,181.85 161
PY2023 $57,423.17 124
PY2024 $65,677.45 161
PY2025 $18,672.96 96

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $494,431.12 30
PY2024 Principal investigator $118,299.84 32
PY2023 Principal investigator $180,488.28 45
PY2022 Principal investigator $345,323.67 36
PY2021 Principal investigator $207,586.30 26
PY2020 Principal investigator $232,727.42 42
PY2019 Principal investigator $196,413.48 41

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

30 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $68.20 12/16/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244045852
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $11,459.52 12/11/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244045894
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $8,703.66 11/20/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244046154
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $61,864.56 11/13/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244046152
Principal investigator 1 GlaxoSmithKline, LLC. $2,050.00 11/03/2025 Non-covered Recipient Entity
ASTHMA ALLERGY ASSOC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192185525
Principal investigator 1 GlaxoSmithKline, LLC. $2,305.00 11/03/2025 Non-covered Recipient Entity
ASTHMA ALLERGY ASSOC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192185529
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $5,631.78 10/30/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244046150
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $5,765.64 10/14/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244046148
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $741.00 10/09/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244046146
Principal investigator 1 AstraZeneca UK Limited $33,536.00 09/26/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK
a phase two a,randomized,double blind,placebo controlled study to assess efficacy and safety of atuliflapon given orally once daily for twelve weeks in adults with moderate to severe uncontrolled asthma No dispute reported 06/30/2026 1185537655
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,000.00 09/18/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244046270
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $12,748.56 09/17/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244046144
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $15,647.72 09/11/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244046142
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $13,130.70 08/21/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244046140
Principal investigator 1 GlaxoSmithKline, LLC. $19,300.00 08/01/2025 Non-covered Recipient Entity
ASTHMA ALLERGY ASSOC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192185532
Principal investigator 1 GlaxoSmithKline, LLC. $2,788.00 07/28/2025 Non-covered Recipient Entity
ASTHMA & ALLERGY ASSOCIATES PC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192187103
Principal investigator 1 GlaxoSmithKline, LLC. $17,019.90 07/28/2025 Non-covered Recipient Entity
ASTHMA & ALLERGY ASSOCIATES PC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192187107
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $8,748.51 07/24/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244046138
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $68.20 07/23/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244045850
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $27,861.51 06/24/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244046136
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $10,763.57 05/08/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244046336
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $15,285.14 04/24/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244046334
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $68.20 04/03/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244046056
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $7,243.89 03/20/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244046332
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $6,246.53 03/06/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244046330
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $204.60 02/28/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244046054
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $19,727.35 02/13/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244046328
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $9,028.33 01/30/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244046326
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,040.72 01/16/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244046324
Principal investigator 1 Eli Lilly and Company $172,384.33 01/03/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LEBRIKIZUMAB/ LY3650150 IN ADULT PARTICIPANTS WITH PERENNIAL ALLERGIC RHINITIS No dispute reported 06/30/2026 1187880645